Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Aug 4;17(8):e0270907. doi: 10.1371/journal.pone.0270907

LTβR overexpression promotes plasma cell accumulation

Jessica A Kotov 1, Ying Xu 1, Nicholas D Carey 2, Jason G Cyster 1,*
Editor: Antonio Solimando3
PMCID: PMC9352096  PMID: 35925983

Abstract

Multiple myeloma (MM), a malignancy of plasma cells (PCs), has diverse genetic underpinnings and in rare cases these include amplification of the lymphotoxin b receptor (Ltbr) locus. LTβR has well defined roles in supporting lymphoid tissue development and function through actions in stromal and myeloid cells, but whether it is functional in PCs is unknown. Here we showed that Ltbr mRNA was upregulated in mouse PCs compared to follicular B cells, but deficiency in the receptor did not cause a reduction in PC responses to a T-dependent or T-independent immunogen. However, LTβR overexpression (OE) enhanced PC formation in vitro after LPS or anti-CD40 stimulation. In vivo, LTβR OE led to increased antigen-specific splenic and bone marrow (BM) plasma cells responses. LTβR OE PCs had increased expression of Nfkb2 and of the NF-kB target genes Bcl2 and Mcl1, factors involved in the formation of long-lived BM PCs. Our findings suggest a pathway by which Ltbr gene amplifications may contribute to MM development through increased NF-kB activity and induction of an anti-apoptotic transcriptional program.

Introduction

Multiple myeloma (MM), the second most common hematologic malignancy in the world, is characterized by an overaccumulation of monoclonal plasma cells (PCs) in the bone marrow (BM). MM is a heterogeneous disease in that providing a singular treatment to a large group of MM patients may improve survival for only a subset of them. Patients differ in genetic translocations, mutations, clonality, dependence on anti-apoptotic proteins, etc. [1, 2]. Clinically, there is increasing evidence that it is important to identify the optimal treatment regimen for each subset of MM patients [36].

Genetic studies on MM identified abnormalities associated with constitutive activation of the NF-kB pathway in ~20% of cases [7, 8]. Signaling to NF-kB occurs via canonical and non-canonical pathways and derangements in either pathway are associated with MM. Several receptors can activate NF-kB signaling in B cells including the BCR, TLRs and TNF receptor family members with the latter being most effective in engaging the non-canonical NF-kB pathway [9]. The critical role of NF-kB signaling in MM pathogenesis is supported by the clinical success of proteasome inhibitors in patients with relapsed, refractory myeloma [10] that partly act through NF-kB inhibition [11]. As well as having cell intrinsic effects, NF-kB signaling can induce adhesion molecules such as ICAM1 and this may favor microenvironment interactions that contribute to disease pathogenesis [12, 13].

The LTβR is a TNFR family member that responds to the ligands LTα1β2 and LIGHT [14]. The best-defined role of the LTβR is in lymphoid tissue neogenesis and mice lacking this receptor or downstream components of the non-canonical NF-kB signaling pathway lack lymph nodes and have a disorganized spleen. LTβR signaling is needed within lymphoid stromal cells for expression of homeostatic chemokines and for the development of follicular dendritic cells. LTβR is also expressed in myeloid cells and is important for the homeostasis and function of certain subsets of dendritic cells (DCs), macrophages and granulocytes [1517]. In contrast to these well-defined stromal and myeloid roles of the LTβR, whether the receptor has a function in B lineage cells has not been determined.

In a study that examined MM samples for gene amplification, rare cases of LTβR amplification were detected [8]. This finding raised questions about whether the LTβR was normally expressed or functional within B lineage cells, and whether over-expression could contribute to MM pathogenesis. Here we report that LTβR is upregulated during PC development, but it does not appear to be essential for normal PC accumulation. However, overexpression (OE) of the LTβR in mouse B cells led to enhanced PC formation in vitro and in vivo. This gain-of-function effect was ligand independent. Quantitative PCR (qPCR) analysis revealed that LTβR OE PCs had enhanced expression of Nfkb2, Bcl2 and Mcl1. This work suggests that gene amplifications leading to LTβR OE contribute to non-canonical NF-kB signaling and thereby promote anti-apoptotic factor expression and PC survival.

Materials and methods

Mice, cell isolations, Abs, flow cytometry, qPCR

C57BL/6 (B6) and B6-CD45.1 mice were obtained from The Jackson Laboratory or National Cancer Institute. Blimp1-GFP, CD19-Cre+/-, B6 Ltbr-/-, and Mb1-cre+/- were from The Jackson Laboratory or a colony maintained at UCSF. B6 Ltb-/- and B6 Ltbrfl/fl mice were provided by Alexander Tumanov’s laboratory. Mice were maintained and all experiments were performed in accordance with IACUC-approved guidelines at the Laboratory Animal Resource Center (LARC) facility at UCSF. The health and well-being of the mice were monitored daily by a qualified LARC staff member. All efforts were made to minimize and alleviate distress and suffering. Mice were anesthetized in chambers connected to isoflurane and oxygen sources prior to i.v. or i.p. injection. Mice were euthanized according to institutional guidelines involving CO2 exposure followed by cervical dislocation. BM chimeras were generated by lethal irradiation with 1200 rad from a cesium irradiator (split dose separated by 3 h) followed by i.v. injection with relevant BM cells. Both male and female mice were used as donors and recipients.

PCs cells were isolated by labeling spleen or BM cells with anti-CD138 antibodies conjugated to PE or APC and applying the relevant fluorophore-specific isolation kits (Stemcell Technologies). B cells were purified from splenocytes by incubating cells with biotin-conjugated Abs specific to non-B cells followed by staining with streptavidin rapidspheres and magnetic separation (Stemcell Technologies). Blocking of the LTβR ligands LTα1β2/LIGHT was assessed through the addition of 4 ug/ml of human LTβR-Fc [18] to the in vitro culture. NP-specific B cells were labeled using NP16-PE (Biosearch Technologies) or NP18-CGG-FITC (Biosearch Technologies). The SA-PE-AF647 reagent was created by applying the AF647 labeling kit (life technologies) on SA-PE (Prozyme).

Abs used for depletion and staining were purchased from BD Biosciences, Biolegend, Invitrogen Life Technologies, and eBioscience. Fluorescently labeled cells were analyzed using an Aurora flow cytometer (Cytek). FACS sorting was performed on an Aria (BD). Flow cytometry plots were analyzed using Flowjo (Treestar).

For qPCR, RNA was prepared from sorted cells or spleen using a RNeasy kit (Qiagen) with the following primers/probes (Integrated DNA Technologies): Ltbr forward primer 5′-CCAGATGTGAGATCCAGGGC-3′, reverse primer 5′-GACCAGCGACAGCAGGATG-3′; Nfkb2 (P100) forward primer 5′- AGCCCCTGAGACAGCTGATG-3′, reverse primer 5′-GGCCTTCACAGCCATATCGA-3’; Bcl2 forward primer 5’- GTACCTGAACCGGCATCTGC-3’, reverse primer 5’- AAACAGAGGTCGCATGCTGG-3’; Mcl1 forward primer 5’- TTGTAAGGACGAAACGGGACTG-3’, reverse primer 5’- TTCTGATGCCGCCTTCTAGGT-3’; and hypoxanthine phosphoribosyl transferase (Hprt) forward primer 5’- AGGTTGCAAGCTTGCTGGT-3’, reverse primer 5’-TGAAGTACTCATTATAGTCAAGGGCA-3’. Transcript levels were detected on an ABI 7700 sequence instrument (Taqman; PE Applied Biosystems).

Immunizations

For NP-CGG/Alum immunizations, each mouse received an i.p. injection containing 100 ug of NP-CGG (Biosearch Technologies) in 100 ul of PBS mixed with 100 ul of Alhydrogel alum adjuvant (Invivogen). For NP-Ficoll immunizations, each mouse received an i.p. injection containing 75 ug of NP54-AECM-Ficoll (Biosearch Technologies) in 200 ul of PBS.

Vectors, retroviral transductions and chimeras

BM retroviral transductions were performed as previously described [19] using the Platinum-E packaging cell line (Cell Biolabs) and lipofectamine 2000 (Thermo Fisher Scientific). DNA used for transfection was Empty-MSCV-Thy1.1, Ltbr-MSCV-Thy1.1 and loxp-EGFP-stop-loxp-Ltbr-MSCV-Thy1.1 vectors [19].

In vitro culture

Isolated B cells were plated in flat bottom 24 well plates with 1x106 B cells per well.

The cells were stimulated with 10 ug/ml of LPS from Escherichia coli (Sigma-Aldrich) or 125 ng/ml anti-CD40 (FGK45.5; Miltenyi) with 25 ng/ml IL-4 (Peprotech), 5 ng/ml IL-5 (Peprotech), 25 ng/ml IL-21 (Tonbo Biosciences) in RPMI 1640 media (Fisher) containing 10% FBS (Omega Scientific), penicillin-streptomycin, glutamax, MEM non-essential amino acids, sodium pyruvate and 2-mercaptoethanol (media supplements from Gibco unless otherwise stated) for 3 days.

Statistical analysis

Statistical tests were performed using Prism (Graphpad) software and p values were obtained using two-tailed unpaired t tests with a 95% confidence interval. S1 File contains the values used to generate prism plots for all the figures.

Results

Endogenous Ltbr expression in PCs

We assessed LTβR expression by B cells through qPCR analysis of various B cell subsets. CD138+TACI+CD98+ cells consisting of CD138+Blimp1-GFPINT immature PCs or Blimp1-GFPHI mature PCs were magnetically enriched and then FACS sorted (Fig 1A). Multiple cell types in the spleen, including stromal cells, DCs, macrophages and granulocytes, express Ltbr transcripts (Immgen.org) and mRNA from total spleen tissue was used as a positive control. Ltbr was undetectable in follicular (FO) or germinal center (GC) B cells but was upregulated in Blimp1-GFPINT immature and Blimp1-GFPHI mature PCs in spleen and BM (Fig 1B). In accord with the low transcript abundance and the low sensitivity of flow cytometric staining compared to qPCR, we were unable to detect LTβR protein on the surface of PCs (Fig 1C).

Fig 1. LTβR expression in B lineage cells.

Fig 1

(A) Blimp1-GFP mice were immunized with NP-CGG/Alum, reimmunized with the same immunogen after 3 weeks and analyzed 4 days later. PCs were positively enriched from spleen and BM cells by CD138 PE magnetic bead-based selection and FACS sorted for qPCR analysis. Representative FACS plots of live Dump (CD4, CD8, F4/80, Ly6G)-B220+ cells with gates on TACI+CD98+ cells consisting of CD138+ Blimp1-GFPINT immature PCs or Blimp1-GFPHI mature PCs. (B) Ltbr gene expression relative to Hprt among total spleen cells, CD8-Gr-1-F4/80-Dead- B220+IgD+ FO B cells, B220+PNA+GL7+IgD- GC B and PCs. FO and GC B cells were FACS sorted from spleens of WT mice immunized with NP-CGG/Alum for 11 days. (C) LTβR protein expression by flow cytometry in LTβR-deficient (Ltbrfl/fl Mb1-cre+/-) and WT (Ltbr+/+ Mb1-cre+/-) PCs. Data shown in all panels are representative of two independent experiments. Pooled data from two independent experiments are shown (n = 4–6 mice per group for A-B and n = 3 for C). * p < 0.05, ** p < 0.01.

Intact PC responses by LTβR-deficient B cells to T cell-dependent and -independent immunogens

The role of LTβR in the B lineage was explored by analyzing chimeras containing CD45.2+ C57BL/6J or LTβR-/- BM cells mixed with CD45.1+ wild-type BM cells at a 30:70 ratio, in CD45.1+ recipients. After 8 weeks of reconstitution, the chimeric mice were immunized with the T cell-dependent antigen NP-CGG/Alum two times, 21 days apart, and analyzed 28 days after the booster immunization. A late timepoint following an antigen booster immunization served the purposes of examining the potential survival benefits of LTβR on long-lived spleen and BM PCs as well as examining a larger number of antigen-specific BM PCs. Chimerism was assessed by comparing the CD45.2 and CD45.1 frequencies by flow cytometry analysis of the B220-expressing FO B cell populations (Fig 2A and 2B, top). The influence of LTβR on total and NP+ GC B cells and memory B cells was examined by comparing the CD45.2 and CD45.1 ratio against that of the starting FO B cells (Fig 2A and 2B, middle-bottom). Given the low to undetectable expression of Ltbr in GC B cells (Fig 1B) and memory B cells (Immgen.org), it was as expected for LTβR to not play a role in the development of these B cell subsets. The potential role of the LTβR in the PC compartment was assessed by analysis of total and NP+ PCs in the spleen and BM. LTβR deficiency did not cause a significant change in PC frequencies in either organ (Fig 2C and 2D).

Fig 2. LTβR expression in B cells is not required for PC responses to a T-dependent antigen.

Fig 2

(A) Diagram of experimental scheme. Chimeras were made by mixing CD45.2+ WT or Ltbr-/- BM cells with CD45.1+ wild-type cells at a 30:70 ratio and injecting into irradiated CD45.1+ recipients. After 8 weeks of reconstitution, mice were immunized with NP-CGG/Alum two times 21 days apart and analyzed 28 days after the booster immunization. (B) FACS plots of singlet cells with a gate on live Dump-B220+ cells (top row, left). The B220+ cells were further gated on IgD+GL7- FO B cells (top row, middle), with further gates on CD45.2+ or CD45.1+ cells (top row, right). Alternatively, B220+ cells were gated based on CD38-GL7+ GC B cells (middle row, left) with further gates on CD45.2+ or CD45.1+ cells (middle row, middle). NP+ GC B cells were identified as NP16-PE+ and decoy SA-PE-AF647- (middle row, right). Memory B cells were identified as CD38+GL7-CD95+IgD- (bottom row, left) with gates on CD45.2+ or CD45.1+ cells (bottom row, middle) or NP+ memory B cells (bottom row, right). (C) Chimerism based on the ratio of CD45.2+ WT or Ltbr-/- to CD45.1+ WT FO B cells (top). GC B cell ratio of CD45.2+ cells to CD45.1+ cells normalized to the FO B cell ratio (middle). Memory B cell ratio of CD45.2+ cells to CD45.1+ cells normalized to the FO B cell ratio (bottom). (D) Representative FACS plots of CD138-enriched BM cells from a CD45.2+ WT recipient chimera pre-gated on live Dump-B220loCD138+ cells. PCs were identified as B220- (left), TACI+CD98+ (top row, middle) with gates on CD45.2+ or CD45.1+ cells (top row, right). NP-CGG+ PCs were identified as NP-CGG-FITC+ (bottom row, left) with further gates on CD45.2+ or CD45.1+ cells (bottom row, right). (E) Ratio of CD45.2+ cells to CD45.1+ cells normalized to the FO B cell ratio for spleen PCs (top) or BM PCs (bottom). Data shown in all panels are representative of two independent experiments (n = 4–5 mice per group).

We next asked whether LTβR expression impacts PCs induced by a T cell-independent immunogen. This was examined by immunizing Ltbrfl/fl Mb1-cre+/- or control (Ltbrfl/fl or Ltbrfl/+ Mb1-cre+/-) mice with NP-Ficoll and examining the total and NP+ PCs in the spleen by flow cytometry after 11 days (Fig 3A). Quantification of the PCs in these B cell specific LTβR-deficient mice indicated a lack of importance for B lineage LTβR expression on early T cell independent PCs (Fig 3B). These data indicate LTβR is not critical for PC accumulation under the T-dependent or T-independent immunization conditions tested.

Fig 3. LTβR expression in B cells is not required for PC responses to a T-independent antigen.

Fig 3

Ltbrfl/fl Mb1-cre+/- or control (Ltbrfl/fl or Ltbrfl/+ Mb1-cre+/-) mice were immunized with NP-Ficoll for 11 days. (A) Representative FACS plots of live Dump- CD138-enriched splenocytes from an unimmunized Ltbrfl/fl mouse and immunized mice (top row) with gates on TACI+CD98+ PCs. NP+ PCs cells were identified as NP16-PE+ and decoy SA-PE-AF647- (bottom row). (B) Numeration of total and NP+ PCs in spleens of immunized mice. Data shown in all panels are representative of two independent experiments (n = 4–5 mice per group).

LTβR OE results in greater PC accumulation after in vitro stimulation independently of ligand

Given the cases of Ltbr amplification found in MM patients, it seemed possible that LTβR overactivation promotes PC accumulation or survival. This hypothesis was tested by creating BM chimeras that OE LTβR specifically in the CD19+ B cell compartment. Chimeras were made by retroviral transduction of CD45.2+ CD19-Cre+/- BM with Empty-MSCV-Thy1.1 control or loxp-EGFP-stop-loxp-Ltbr-MSCV-Thy1.1 retrovirus prior to transfer into irradiated CD45.1+ host mice. Expression of Cre recombinase by CD19+ cells leads to excision of the loxp-EGFP-STOP-loxp sequence and subsequent expression of the downstream Ltbr gene. Therefore, Thy1.1+ non-B cells that do no express CD19 in loxp-EGFP-stop-loxp-Ltbr-MSCV-Thy1.1 chimeric mice co-express eGFP while Thy1.1+ non-B cells in Empty-MSCV-Thy1.1 chimeric mice do not (Fig 4A).

Fig 4. OE of LTβR increases PC numbers in vitro in response to LPS or anti-CD40 stimulation in the absence of ligand.

Fig 4

(A) Diagram of experimental scheme. Chimeras were made by retroviral transduction of CD45.2+ CD19-Cre+/- BM with Empty-MSCV-Thy1.1 or loxp-EGFP-loxp-LTβR-MSCV-Thy1.1 retrovirus and transfer into irradiated CD45.1+ recipients. After reconstitution, B cells were isolated from the spleen for in vitro culture. (B) Representative FACS plots of CD45.2+B220- splenocytes in chimeras stimulated with or anti-CD40 with IL-4, IL-5, and IL-21 for 3 days. Transduction efficiency based on Thy1.1 expression on FO B cells was 43–93% among the mice analyzed. Blocking of the LTβR ligands was assessed through the addition of human LTβR-Fc blocking antibody. (C) FACS plots of live Dump-B220+CD45.2+ B cells with gates on Thy1.1+ cells and further gates on CD98+CD138+ PCs. (D) Percentages of CD98+CD138+ PCs among Thy1.1+ (left) and Thy1.1- (right) B cells as gated in B. Numbers of CD98+CD138+ Thy1.1+ PCs (middle). (E) LTβR protein expression by flow cytometry of WT B cells stimulated with LPS for 3 days and retrovirally transduced with Empty-MSCV-Thy1.1 or LTβR-MSCV-Thy1.1 vectors. (F) Frequency of CD98+CD138+ PCs among Thy1.1+ transduced WT or Ltb-/- B cells stimulated with LPS media for 3 days. Data shown in all panels are representative of two independent experiments (n = 2–3 mice per group). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

B cells were isolated from spleens and in vitro activated for 3 days with stimuli that mimic T cell-independent (LPS) or T cell-dependent (anti-CD40 and cytokines) responses. Transduced B cells OE LTβR were identified as Thy1.1+eGFP- (Fig 4B). The ability of LTβR OE Thy1.1+ B cells or control Thy1.1+ B cells to form CD98+CD138+ PCs was quantified. OE of LTβR strongly enhanced the ability of B cells to form PCs after both LPS and aCD40 stimulations (Fig 4B and 4C, left and middle). This PC enhancement was not at the expense of Thy1.1- cells in the LPS condition, but was in the aCD40 condition (Fig 4C, right). It is possible that the remarkably strong augmentation of PC accumulation caused by LTβR OE in the aCD40 culture condition led to depletion of factors needed for accumulation of wild type (WT) PCs.

LTβR OE as a result of retroviral transduction was confirmed by detecting LTβR protein expression in transduced B cells using flow cytometric analysis (Fig 4D). Whether LTβR ligand was required for LTβR OE to enhance PC accumulation was tested by blocking any LTβR ligand that may have been available from cells in the culture using soluble LTβR-Fc [20]. Inclusion of this antagonist did not impact PC formation by LTβR OE cells (Fig 4C) indicating that LTβR OE leads to greater PC differentiation independently of LTβR ligands. This was further supported by the finding that LTβ-deficient B cells, which are unable to form the LTβR ligand LTα1β2 on the surface, fully retained the ability to form increased frequencies of PCs under conditions of LTβR OE (Fig 4E).

LTβR OE promotes antigen-specific PC formation in the spleen and BM in response to immunization

The influence of LTβR OE on PC frequencies was assessed in vivo in retroviral BM chimeras containing control or LTβR OE B cells that were identified based on donor CD45.2 expression and the transduction marker Thy1.1. The mice were immunized with NP-CGG/Alum two times 21 days apart and after 26 days from the booster immunization, spleens and BM were analyzed. Efficiency of the retroviral transduction was assessed by quantifying the Thy1.1 frequency among the FO B cell population, which ranged from 3–56% (Fig 5A and 5B). Thy1.1 reporter+ cells were represented in the GC compartment at similar frequencies as in the FO compartment, suggesting that LTβR expression does not influence the GC response (Fig 5C). Assessment of the numbers of total PCs and NP+ PCs in the spleen and BM showed that all the mice mounted similar overall responses (Fig 5D–5F). The influence of LTβR on PC accumulation was assessed by comparing the Thy1.1 frequency of PCs to the starting Thy1.1 frequency of FO B cells in each mouse (Fig 5G). Importantly, total and NP+ LTβR OE PCs strongly over accumulated in the spleen and BM (Fig 5G) indicating that elevated LTβR expression is sufficient to augment PC accumulation in vivo.

Fig 5. LTβR OE promotes PC accumulation in vivo.

Fig 5

(A) Diagram of experimental scheme. Chimeras were made by retroviral transduction of CD45.2+ WT BM with Empty-MSCV-Thy1.1 or LTβR-MSCV-Thy1.1 (LTβR OE) retrovirus and transfer into irradiated CD45.1+ recipients. After reconstitution, mice were immunized with NP-CGG/Alum two times 21 days apart. After 26 days from the booster immunization, spleen and BM were analyzed. (B) Representative flow plots representing Dump-B220+CD45.2+CD45.1-IgD+ spleen FO B cells with gates on Thy1.1+ cells. (C) Thy1.1 frequency of FO B cells. (D) Thy1.1 frequency of spleen GC B cells normalized to Thy1.1 frequency of FO B cells in matched mice. (E) FACS plots of Dump-CD138+CD45.2+ cells with gates on B220-, TACI+CD98+ PCs with further gates on Thy1.1 cells among total spleen PCs or (F) NP+ spleen PCs. NP+ PCs were identified as NP16-PE+ and decoy SA-PE-AF647-. (G) Number of total spleen or BM PCs (left) and NP frequency of PCs (right). (H) Thy1.1 frequency of spleen or BM PCs normalized to Thy1.1 frequency of FO B cells in matched mice. Data shown in all panels are representative of two independent experiments (n = 6–8 mice per group). * p < 0.05, ** p < 0.01.

LTβR OE PCs have increased transcription of NF-kB and anti-apoptotic genes

We hypothesized that LTβR OE of B cells was leading to the overaccumulation of PCs in vivo at least in part by promoting a transcriptional program that prevents cell death. To test this possibility, control and LTβR OE spleen PCs from retroviral BM chimeras were FACS sorted as in Fig 1 and analyzed for transcription of known PC-related pro-survival genes by qPCR analysis. As expected, LTβR OE PCs exhibited elevated transcription of Nfkb2, a non-canonical NF-kB related gene that is induced by NF-kB (Fig 6). Furthermore, OE of LTβR led to elevated transcription of the NF-kB target genes Bcl2 and Mcl1 (Fig 6), anti-apoptotic factors involved in the formation and maintenance of long-lived BM PCs [21, 22]. Our findings suggest a role for LTβR in enhancing non-canonical NF-kB activity and induction of an anti-apoptotic transcriptional program when overexpressed in PCs.

Fig 6. LTβR OE PCs have greater transcription of Nfkb2, Bcl2, and Mcl1.

Fig 6

B cell specific LTβR OE or control chimeras were generated as in Fig 4. Dump-CD138+B220-TACI+CD98+CD45.2+ Thy1.1+ or Thy1.1- PCs were sorted from spleens. qPCR analysis was conducted to determine the transcription levels of Nfkb2, Bcl2, and Mcl1. Control samples consist of Thy1.1+ or Thy1.1- PCs from Empty-MSCV-Thy1.1 chimeras and Thy1.1- PCs from loxp-EGFP-loxp-Ltbr-MSCV-Thy1.1 chimeras. In some instances, cells from multiple mice were combined into one sample to obtain sufficient cells for analysis. Pooled data from two independent experiments are shown. * p < 0.05, ** p < 0.01.

Discussion

Our work establishes that Ltbr mRNA is upregulated in PCs compared to FO B cells. Although the expression is low in normal PCs, the locus activity is likely important for enabling high expression of the LTβR in pre-malignant PCs on occasions when locus amplification occurs. Our mouse modeling work shows that elevated LTβR expression in B lineage cells is sufficient to promote elevated PC expression of anti-apoptotic genes and increased PC accumulation (Fig 7). The findings are consistent with the conclusion that Ltbr amplifications are one of the mechanisms by which NF-kB signaling can become deregulated in PCs, contributing to their accumulation and malignant progression.

Fig 7. Model for LTβR over-expression (OE) effect on PC accumulation.

Fig 7

In WT PCs, TACI and BCMA are highly expressed while LTβR expression is very low. Under conditions where LTβR is OE, there is an overall increase in signaling via NF-kB leading to augmented Bcl2-family protein expression and reduced apoptosis, and to increases in other NF-kB target genes that augment PC accumulation. While TACI and BCMA signaling is ligand (BAFF, APRIL) dependent, the OE LTβR may signal in a ligand independent manner. Chronic LTβR OE in PCs due to gene amplification may allow marked over accumulation of PCs, increasing the chances of additional genetic variants emerging and progression to MM.

A recent genome wide OE screen identified LTBR as the gene that was most potent in promoting human T cell effector function and preventing exhaustion [23]. Taking a similar cell engineering perspective, our data suggest that increasing LTβR expression in engineered B lineage cells may be an approach to augment the generation of plasma cells and the associated production of antibody or introduced secretory proteins.

Our findings indicate that LTβR OE can promote PC accumulation in a ligand-independent manner. In accord with this result, OE of the LTβR in HEK293 cells that lack expression of LTα1β2 or LIGHT was sufficient to activate the NF-kB pathway [24]. These data do not exclude the possibility that LTβR OE cells signal more strongly in the presence of ligand. Multiple cell types in mouse and human BM express LTα1β2 and Tnfrsf14 (LIGHT) (Immgen.org; HCA BM viewer). Moreover, there is evidence for LTβR signaling in the BM acting to influence granulocyte metabolism [25], HSC maintenance [26], and mesenchymal cells [27]. As well as LTβR, MM can strongly OE CD40 and TACI (TNFRSF13B) [7, 8]. Our findings add support to the possibility that these additional TNFR family members signal constitutively in PC when OE, thereby contributing to malignant progression. In the case of the LTβR, ligand independent signaling may limit the possible efficacy of LTβR antagonism as an approach to treat LTβR OE MM. Instead, better therapeutic effect may be achieved with inhibitors of downstream components such as NF-kB.

Our observation that LTβR OE promotes increased PC transcription of both the non-canonical NF-kB related gene Nfkb2 and the anti-apoptotic gene Bcl2 is in agreement with studies indicating that p52 (encoded by Nfkb2) drives Bcl2 transcription in mouse splenic B cells [28]. In addition, there are NF-kB binding sites in the BCL-2 promoter that can be bound and transactivated by p50 or p52 homodimers [29]. Furthermore, OE of NF-kB2-encoded p100 and its processed product p52 can induce BCL-2 expression [29]. Mcl-1 is another anti-apoptotic protein that plays a significant role in the pathogenesis of various human tumors including MM [30]. Mcl-1 induction has been linked to the canonical NF-kB pathway [31]. Furthermore, normal PCs depend on Mcl-1 for maintenance in the BM and TNFRSF17 (BCMA) signals via NF-kB to promote Mcl1 expression [22]. These studies support the conclusion that LTbR signaling via NF-kB promotes PC accumulation in part through induction of Bcl2 and Mcl1. It is likely that additional pathways not examined here also contribute to LTbR OE-induced PC accumulation. These data also point to the possible value of testing Bcl2 and Mcl1 antagonists in the treatment of LTβR OE MM [32].

A limitation in our OE studies is that Ltbr was over-expressed in all B lineage cells and it is possible that PC accumulation was secondary to effects of the receptor in an earlier stage of B cell development. However, we did not observe any effect of Ltbr OE on the fraction of B cells in the GC versus FO compartment, providing one line of evidence that receptor expression was not causing marked changes in all B cell compartments. Moreover, it is possible that the Ltbr amplifications observed in MM occur during the gene rearrangements events associated with B cell development rather than selectively in at the PC stage. Our findings suggest that even when gene amplifications occur early in the B lineage, the effect may not manifest until the PC stage.

The LTβR is broadly expressed by myeloid cells (Immgen.org) and we speculate that downregulation of the B lineage-defining transcription factor Pax5 during PC differentiation [33] allows de-repression of the LTβR locus. Conditional removal of Pax5 from mature B cells allows their reverse differentiation toward the myeloid lineage [34]. The loss of Pax5 expression leads to profound changes in locus accessibility in B cells and this presumably also occurs during the natural repression of Pax5 in PCs, but it is unclear what fraction of the de-repressed genes are of physiological importance in PCs. Although our studies have not identified a role for LTβR expression in normal PC accumulation, they do not exclude an influence of this receptor under some conditions such as in promoting PC longevity over periods of months to years or contributing to survival in inflammatory niches that may be high in LTα1β2 and LIGHT compared to BCMA and TACI ligands.

Supporting information

S1 File. This supporting information file includes the values used to generate prism plots for all the figures.

(XLSX)

Acknowledgments

The authors thank Alexander Tumanov for sharing Ltb-/- and Ltbrfl/fl mice, Jinping An for help with mouse genotyping, and the Cyster lab members for input on this project.

Abbreviations used in this article

OE

overexpression

PCs

plasma cells

BM

bone marrow

DCs

dendritic cells

qPCR

quantitative PCR

GC

germinal center

FO

follicular

ILC

innate lymphoid cell

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by the Howard Hughes Medical Institute funding to J.G.C. and J.A.K. National Institutes of Health Grants (R01 AI040098, R01 AI045073 to J.G.C.; T32 AI007334 to J.A.K.) and the Life Sciences Research Foundation Postdoctoral Fellowship to J.A.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546. doi: 10.1155/2014/232546 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30(3):761–4. doi: 10.1038/leu.2015.184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Caers J, Garderet L, Kortum KM, O’Dwyer ME, van de Donk N, Binder M, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103(11):1772–84. doi: 10.3324/haematol.2018.189159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Spat-Schwalbe E, Goede V, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105(5):1183–8. doi: 10.3324/haematol.2019.242958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660–75. doi: 10.1182/blood-2018-09-825331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, et al. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells. 2020;9(1). doi: 10.3390/cells9010167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115–30. doi: 10.1016/j.ccr.2007.07.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131–44. doi: 10.1016/j.ccr.2007.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545–58. doi: 10.1038/nri.2017.52 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–17. doi: 10.1056/NEJMoa030288 [DOI] [PubMed] [Google Scholar]
  • 11.Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630–9. doi: 10.1200/JCO.2005.11.030 [DOI] [PubMed] [Google Scholar]
  • 12.Antonio G, Oronzo B, Vito L, Angela C, Antonel-la A, Roberto C, et al. Immune system and bone microenvironment: rationale for targeted cancer therapies. Oncotarget. 2020;11:480–7. doi: 10.18632/oncotarget.27439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Solimando AG, Da Via MC, Leone P, Borrelli P, Croci GA, Tabares P, et al. Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica. 2021;106(7):1943–56. doi: 10.3324/haematol.2019.239913 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol. 2005;23:787–819. doi: 10.1146/annurev.immunol.23.021704.115719 [DOI] [PubMed] [Google Scholar]
  • 15.Ehlers S, Holscher C, Scheu S, Tertilt C, Hehlgans T, Suwinski J, et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol. 2003;170(10):5210–8. doi: 10.4049/jimmunol.170.10.5210 [DOI] [PubMed] [Google Scholar]
  • 16.Kabashima K, Banks TA, Ansel KM, Lu TT, Ware CF, Cyster JG. Intrinsic Lymphotoxin-beta Receptor Requirement for Homeostasis of Lymphoid Tissue Dendritic Cells. Immunity. 2005;22(4):439–50. doi: 10.1016/j.immuni.2005.02.007 [DOI] [PubMed] [Google Scholar]
  • 17.Wege AK, Huber B, Wimmer N, Mannel DN, Hehlgans T. LTbetaR expression on hematopoietic cells regulates acute inflammation and influences maturation of myeloid subpopulations. Innate Immun. 2014;20(5):461–70. doi: 10.1177/1753425913497242 [DOI] [PubMed] [Google Scholar]
  • 18.Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000;406(6793):309–14. doi: 10.1038/35018581 [DOI] [PubMed] [Google Scholar]
  • 19.Green JA, Suzuki K, Cho B, Willison LD, Palmer D, Allen CD, et al. The sphingosine 1-phosphate receptor S1P(2) maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 2011;12(7):672–80. doi: 10.1038/ni.2047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev. 2008;223:202–20. doi: 10.1111/j.1600-065X.2008.00633.x [DOI] [PubMed] [Google Scholar]
  • 21.Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci U S A. 2010;107(24):10967–71. doi: 10.1073/pnas.1005256107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Peperzak V, Vikstrom I, Walker J, Glaser SP, LePage M, Coquery CM, et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol. 2013;14(3):290–7. doi: 10.1038/ni.2527 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature. 2022;603(7902):728–35. doi: 10.1038/s41586-022-04494-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Maminska A, Bartosik A, Banach-Orlowska M, Pilecka I, Jastrzebski K, Zdzalik-Bielecka D, et al. ESCRT proteins restrict constitutive NF-kappaB signaling by trafficking cytokine receptors. Sci Signal. 2016;9(411):ra8. doi: 10.1126/scisignal.aad0848 [DOI] [PubMed] [Google Scholar]
  • 25.Riffelmacher T, Giles DA, Zahner S, Dicker M, Andreyev AY, McArdle S, et al. Metabolic activation and colitis pathogenesis is prevented by lymphotoxin beta receptor expression in neutrophils. Mucosal Immunol. 2021;14(3):679–90. doi: 10.1038/s41385-021-00378-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hopner SS, Raykova A, Radpour R, Amrein MA, Koller D, Baerlocher GM, et al. LIGHT/LTbetaR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. Nature communications. 2021;12(1):1065. doi: 10.1038/s41467-021-21317-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Heo SK, Choi Y, Jeong YK, Ju LJ, Yu HM, Kim DK, et al. LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells. PLoS One. 2021;16(2):e0247368. doi: 10.1371/journal.pone.0247368 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Xiang H, Wang J, Boxer LM. Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells. Mol Cell Biol. 2006;26(22):8599–606. doi: 10.1128/MCB.01062-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, et al. NF- kappa B2/p100 induces Bcl-2 expression. Leukemia. 2003;17(7):1349–56. doi: 10.1038/sj.leu.2402982 [DOI] [PubMed] [Google Scholar]
  • 30.Kitada S, Reed JC. MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J Natl Cancer Inst. 2004;96(9):642–3. doi: 10.1093/jnci/djh153 [DOI] [PubMed] [Google Scholar]
  • 31.Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie L, et al. Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cell carcinoma cells. BMC Cancer. 2014;14:98. doi: 10.1186/1471-2407-14-98 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120–36. doi: 10.1182/blood.2020006785 [DOI] [PubMed] [Google Scholar]
  • 33.Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 2006;24(3):269–81. doi: 10.1016/j.immuni.2006.01.012 [DOI] [PubMed] [Google Scholar]
  • 34.Mikkola I, Heavey B, Horcher M, Busslinger M. Reversion of B cell commitment upon loss of Pax5 expression. Science. 2002;297(5578):110–3. doi: 10.1126/science.1067518 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Antonio Solimando

25 Apr 2022

PONE-D-22-01475LTβR overexpression promotes plasma cell accumulationPLOS ONE

Dear Dr. Cyster,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 09 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Antonio Solimando

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions

3. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering

Additional Editor Comments (if provided):

The authors are required to carefully answer to the reviewers' comments by providing a rebuttal point by point letter and improve the manuscript accordingly.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors uncovered LTβR overexpression to potentially promote plasma cell accumulation.

Point to be considered:

1. While performing FACS analyses, did the authors employ unstained/isotype controls for compensation?

2. A graphical abstract/figure or panel wummarizing the experimental approach would be beneficial for the reader.

3.When discussing the methodology applied for number selection it is not clear for my understanding, how the author identify or discuss methodologically the experimental in vivo setting. Indeed, in the in vivo experiments, sample size should be calculated in a rigorous way, i.e. by using G*Power software (power of for example 80% and 0.05 statistical level, etc.). For example, assuming an effect-size of for example, 0.4 with statistical significance of α <;0.05 and a power of 80% a given number of 9 mice for each group for a total of 18 mice would be extimated. This number should then be increased to 20 considering an expected drop-out rate of 10% for the treatment. Can the authors comment on this?

4. Cell adhesion molecules, such as ICAM1 and JAMs, are enhanced by tumor cells in a NF-κB-dependent manner in myeloma and its microenvironment: can the authors expand this issue in the introduction/discussion section in order to boost the general interest for a broad readership from the oncology field? Indeed, As is now well known, tumors grow and evolve through a constant crosstalk with the surrounding microenvironment, and emerging evidence indicates that angiogenesis and immunosuppression frequently occur simultaneously in response to this crosstalk. Accordingly, strategies combining anti-angiogenic therapy and immunotherapy seem to have the potential to tip the balance of the tumor microenvironment and improve treatment response (refer to PMID: 32354870 and PMID: 32064051)

Reviewer #2: The authors provide intriguing insights regarding a partially neglected topic in MM, regarding the lymphotoxin b receptor (Ltbr) locus. LTβR has well defined roles in supporting lymphoid tissue development and function through actions in stromal and myeloid cells.

Point to be addressed:

1. Are the presented data following a normal (Gaussian) distribution? If this is the case, this should be clearly stated, and parametric tests can be performed. If this is not the case, non parametric tests should be performe instead

2. I would suggest to better highlight the potential limitations of this study (i.e. how would the authors translate their findings to the clinical side? The underlying message here is that more precision and pinpoint approaches needed to be tested in well designed clinical trials – a challenge, but I would be interested in their perspective of how this might be done).

3. To my knowledge, the role of endothelial lymphotoxin beta receptor (LTβR) has been described to egress lymphoid organ (in this regard endothelial cells can be important as well as MM angiogenesis) and ruled out the role of LTβR from epithelial cells or dendritic cells. In this regard, BST-1, like CD38, behaves both as an ectoenzyme and signaling receptor and has been reported to regulate the trafficking of neutrophil and monocytes. Did the authors check for this immune-microenvironmental characteristic or could they envision next step aiming to compensate for this in the next future?

4. In the frame of point 3 thinking, CD38/LTβR could be relevant, given the importance of CD38 targeting in MM: CD31/CD38 axis activates genetic programs relevant for proliferative responses. It also indicates a contribution of this pathway to the processes mediating migration and homing. These results further support the notion that the CD31/CD38 axis is part of a network of accessory signals that modify the microenvironment, favoring localization of MM cells to growth-permissive sites (CD31 is also expressed by endothelial cells). Collectively, the authors finding might hold a theragnostic potential for CD38 targeting and overcoming drug resistance, potentially, these findings may point towards a potential Achilles’ heel of multiple myeloma that might be exploited therapeutically in the future (please refer to PMID: 31936617 and expand introduction/discussion section).

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Antonio Solimando

20 Jun 2022

LTβR overexpression promotes plasma cell accumulation

PONE-D-22-01475R1

Dear Dr. Cyster,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Antonio Solimando

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors have clarified several of the questions raised in the previous reviews. Most of the major problems have been addressed by this revision. The manuscript is considered acceptable for publication.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have clarified several of the questions I raised in my previous review. Most of the major problems have been addressed by this revision.

Reviewer #2: I am satisfied with the answers provided. The authors provided complete explanations and answers to the major issues.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Antonio Solimando

25 Jul 2022

PONE-D-22-01475R1

LTβR overexpression promotes plasma cell accumulation

Dear Dr. Cyster:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Antonio Solimando

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. This supporting information file includes the values used to generate prism plots for all the figures.

    (XLSX)

    Attachment

    Submitted filename: Kotov etal Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES